#pancreatobiliary
Title: An Investigation on the Results of Cytopathologic Tests of Pancreatobiliary Malignancies
Summary: Cytology with EUS-FNA showed good specificity for pancreatobiliary malignancy, and ROSE improved sensitivity. Reporting in a tiered system may reduce nondiagnostic results and repeat sampling.
June 9, 2026 at 11:00 AM
Stones anywhere in your body are no bueno. Glad it’s not the pancreatobiliary system, though.
April 21, 2024 at 3:12 AM
The topics of articles selected for Pancreatobiliary Pathology Society Journal Watch
pbpath.org/journal-watc...
#pbpath #pancreas #pathology #pancreatobiliary #society #journalwatch #articles #vosviewer #bibliometrics
November 10, 2024 at 9:04 AM
Join the International Pancreatobiliary Meeting (IPBM), Seoul, South Korea, April 4th and 5th, 2025

Happy to be part of this meeting!

Abstract submission ends on February 10th!!!

www.ipbm.kr/member/?url=...
IPBM 2025
IPBM 2025
www.ipbm.kr
February 7, 2025 at 11:21 AM
Robust circulating microRNA signature for the diagnosis and early detection of ... - BMC Medici - goo.gl/alerts/pNKV1t #GoogleAlerts
Robust circulating microRNA signature for the diagnosis and early detection of pancreatobiliary cancer - BMC Medicine
Background A new circulating biomarker superior to carbohydrate antigen 19–9 (CA19-9) is needed for diagnosing pancreatobiliary cancer (PBca). The aim of this study was to identify serum microRNA (miR...
goo.gl
January 22, 2025 at 10:51 PM
March 8, 2025 at 1:26 AM
RRIDs were included in this None paper. RRIDs improve reproducibility in scientific research. #reproducibility #methodsmatter #RRID
Directed differentiation of human pluripotent stem cells into pancreatobiliary co-progenitor-like population
doi.org
September 5, 2025 at 7:00 AM
We are thrilled to welcome GI oncologist Gahyun "Gigi" Gim, M.D., to the University of Florida!

Her research interests focus on upper gastrointestinal and pancreatobiliary malignancies.

Get to know her in our physician spotlight: ufhealth.org/stories/2025...
Physician Spotlight: Gahyun Gim, MD, Aims To Be a Lifelong Partner for Gastrointestinal Cancer Patients - UF Health
Gahyun “Gigi” Gim, MD, discovered her calling in gastrointestinal oncology during the third month of her internal medicine residency when she experienced a…
ufhealth.org
June 17, 2025 at 3:10 PM
Epithelial type influences postoperative outcomes in IPMNs

by Yamashige D, Hijioka S (...) Masamune A et 17 al. in J Gastroenterol #Surgery #SurgSky #generalsurgery #MedSky

🪡 read our summary here
📖 read the article:
Clinical impact of epithelial types on postoperative outcomes for intraductal papillary mucinous neoplasms: a multicenter retrospective study - Journal of Gastroenterology
Background Intraductal papillary mucinous neoplasms (IPMNs) are classified into three epithelial types with distinct biological behaviors. However, their effects on the postoperative outcomes remain unclear. Methods This multicenter retrospective study included 556 patients with IPMNs who underwent surgical resection. The epithelial types were categorized into the gastric (n = 323), intestinal (n = 160), and pancreatobiliary (n = 73) types. Their associations with the development of extrapancreatic lesions; remnant high-risk lesions (HRLs), including metachronous pancreatic ductal adenocarcinoma (PDAC); and disease-specific survival (DSS) were analyzed. Results Fifty-one patients (9.2%) developed extrapancreatic lesions. The 10-year cumulative incidence rates for the gastric, intestinal, and pancreatobiliary types were 9.3%, 9.1%, and 32.0%, respectively (P < 0.001). Multivariate analysis identified invasive carcinoma, the gastric, and pancreatobiliary types as independent predictors. Among 516 patients who did not undergo total pancreatectomy, 40 (7.8%) and 13 (2.5%) developed HRLs and metachronous PDAC, respectively. The 10-year cumulative incidence rates of HRLs and metachronous PDAC for the gastric, intestinal, and pancreatobiliary types were 7.0%, 16.2%, and 37.2% and 1.8%, 3.7%, and 22.7%, respectively (P = 0.001 and P = 0.012). In multivariate analysis, the pancreatobiliary type was an independent predictor of metachronous PDAC. Five-year DSS rates for the gastric, intestinal, and pancreatobiliary types were 92.5%, 96.0%, and 76.1% (P < 0.001), respectively. Multivariate analysis identified invasive carcinoma, the gastric, and pancreatobiliary types as independent prognostic factors for DSS. Conclusions IPMN epithelial type can independently affect postoperative outcomes. In particular, the pancreatobiliary type has significant impact on the development of metachronous PDAC. Therefore, postoperative surveillance should be tailored according to the epithelial type.
link.springer.com
February 28, 2025 at 6:36 AM
#MedCase - PEI was diagnosed in a man presenting with unexplained generalized edema.

IgG4-PBD was identified as the leading possible etiology of pancreatic atrophy and exocrine insufficiency, with prior gastrectomy as a modifying factor.

👉️ buff.ly/gAiPrl7

#GISky
Severe pancreatic exocrine insufficiency presenting with hypoalbuminemia, anasarca, and pulmonary edema in a patient with prior gastrectomy and suspected immunoglobulin G4-related pancreatobiliary disease
PEI was diagnosed in a man presenting with unexplained generalized edema. IgG4-PBD was identified as the leading possible etiology of pancreatic atrophy and exocrine insufficiency, with prior…
www.springermedicine.com
August 31, 2026 at 10:54 AM
Another recent study on AST/ALT >1000 again showing:

1. Ischemic hepatitis is clear #1
2. Pancreatobiliary causes are more common than realized
3. Acute hepatitis C now appears to be the most common viral cause

https://onlinelibrary.wiley.com/doi/full/10.1002/jgh3.12224
November 17, 2024 at 2:37 PM
Procedural interventions yield high success rates in Rwanda

by Ingabire Z, Hanna AB (...) Berhane R et 9 al. in BMC Gastroenterol #Surgery #SurgSky #generalsurgery #MedSky

🪡 read our summary here
📖 read the article:
Management and outcomes of patients with obstructive jaundice from pancreatobiliary diseases in Rwanda - BMC Gastroenterology
Background Obstructive jaundice from pancreatobiliary diseases represents a significant global health challenge, particularly in resource-limited settings like Rwanda. While endoscopic retrograde cholangiopancreatography (ERCP) and percutaneous transhepatic biliary drainage (PTBD) are now available at tertiary centers in Kigali, there is limited local clinical data on the management and outcomes of these conditions. This study aims to assess the patterns, therapeutic approaches, and outcomes of obstructive jaundice in the Rwandan healthcare context. Methods A cross-sectional study was conducted across three tertiary hospitals (KFH, RMH, and CHUK) in Rwanda from July 2023 to June 2024. Using Fischer’s formula, 158 patients with obstructive jaundice from pancreatobiliary diseases were enrolled. Data collection involved chart reviews at admission, procedure, post-procedure, discharge, and 30-day follow-up. Analysis was performed using Stata version 13, with descriptive statistics, bivariate analysis using chi-square, and multivariate analyses examining predictors of 30-days mortality among the participants at 95% confidence interval and p value < 0.05 considered statistically significant. Multicollinearity assessment was also performed considering the target variance inflation factor (VIF) < 5. Results In this study of 158 patients with obstructive jaundice in Rwanda, ERCP was the predominant intervention (77.54%), followed by PTBD (17.39%) and surgical procedures (5.07%). The overall procedures technical success rate was 82.61%; with PTBD success rate of 91.67%, surgical procedures showed higher success rate 100%, while ERCP had a success rate of 79.44%. Post-procedure complications occurred in 16.67% of cases, including pancreatitis (5%), bleeding (3.62%), and mortality (4.34%). The 30-day survival rate was 92.41%, demonstrating generally favorable outcomes in managing pancreaticobiliary diseases. The multivariate analysis showed that weight loss increased mortality risk (aOR = 10.647, 95% CI: 1.190-95.256, p = 0.034), while the absence of CBD stones was protective (aOR = 0.087, 95% CI: 0.008–0.888, p = 0.039). Having a procedure performed significantly reduced mortality odds (aOR = 0.025, 95% CI: 0.006–0.117, p < 0.001). ICU/HDU admission was associated with higher mortality risk in 30 days (aOR = 13.051, 95% CI: 2.010-84.731, p = 0.007). Conclusion This study from Rwanda provides crucial insights into the management and outcomes of obstructive jaundice from pancreatobiliary diseases. PTBD was demonstrated high success. While post-procedure complications occurred, the 30-day survival rate was favorable. Weight loss and ICU admission were associated with increased mortality, while procedural interventions showed protective effects, highlighting the importance of timely management.
bmcgastroenterol.biomedcentral.com
August 9, 2025 at 6:44 AM
Porto-mesenteric vein resections show promising postoperative outcomes

by Kapoor D, Bhandare MS (...) Shrikhande SV et 20 al. in Ann Surg Oncol #Surgery #SurgSky #generalsurgery #MedSky

🪡 read our summary here
📖 read the article:
Real-World Evidence of Porto-Mesenteric Vein Resections with Pancreatectomy and the Development of Predictive Clinical Nomograms for Postoperative Outcomes—An Analysis of 389 Cases: The “Porto-Mesenteric Vein Resection-Indian MulticentrE” (PRIME) Study - Annals of Surgical Oncology
Background With better surgery and chemotherapeutic agents, borderline resectable or locally advanced pancreatobiliary tumours are being treated with curative intent. This study presents real-world evidence of porto-mesenteric vein resections (PVR) with pancreatectomy and generates predictive nomograms for postoperative mortality (POM) and major complications (MC). Methods A retrospective multicentre study, including 11 high-volume centres, evaluated patients undergoing PVR. Factors affecting 90-day POM and MC (Clavien-Dindo grades ≥ 3a) were assessed, and predictive nomograms were generated. Overall survival (OS) and disease-free survival (DFS) were estimated for patients with pancreatic ductal adenocarcinoma (PDAC). Cox regression analysis was performed to ascertain factors affecting OS and DFS. Results Among 389 patients, POM was 6.4%, and MCs were 32.6%. Charlson comorbidity index > 4, preoperative biliary drainage, preoperative radiotherapy (PRT), segmental PVR, and additional organ resection (AOR) were predictive of POM. The independent predictors of MCs were American Society of Anesthesiologists status 3/4, PRT, and AOR. The generated model had an area under the curve (AUC) of 0.757, cutoff > 1.79 to predict POM, and AUC of 0.669, cutoff > 0.678 for MCs. In the 263 patients with PDAC, the median OS was 25.01 months (95% confidence interval [CI] 21.9–28.11), and DFS was 16.72 months (95% CI 14.56–18.89). Perineural invasion, segmental PVR, and margin positivity predicted worse survival, while completing multi-modality treatment was protective. Conclusions The POM and MCs of PVR with pancreatectomy were at par with the world standards. The generated predictive nomograms for POM and MC revealed a good predictive potential. In patients with PDAC, completion of multimodality treatment offers better long-term survival.
link.springer.com
July 15, 2025 at 6:46 PM
Extract: The University of Chicago’s Department of Surgery seeks a full-time Surgical Oncologist at Assistant Professor rank, specializing in complex upper gastrointestinal and hepato-pancreatobiliary cancers.
April 28, 2026 at 12:13 AM
Today's speakers include:

Lung - Professor A Nicholson
Haematopathology - Dr A Green
Upper GI - Dr A Cairns
Pancreatobiliary - Dr A Darne
Skin - Dr P Craig
Endocrine - Dr M Moonim
Head and Neck - Dr A Sandison
Breast - Dr E Tjio
March 4, 2025 at 11:14 AM
With a special interest in advanced endoscopy & pancreatobiliary diseases, she`s the Coordinator of the Equality & Diversity Group of the Hellenic Society of Gastroenterology.
2/3
June 25, 2026 at 4:28 PM
Meet one of the ESGE Social Media Working Group members: Elena Manthopuolou⭐
🏥Gastroenterology Department, General Hospital of Nea Ionia – Konstantopouleio‑Patision,
Greece
Elena is a gastroenterologist with a strong focus on pancreatobiliary endoscopy, especially ERCP and EUS
1/3
June 25, 2026 at 4:28 PM
Thanks to Michele Montori, co-editor of the ESGE Academy Working Group for providing the content of this post.

#ERCP #Ampulla #Endoscopy #GIEndoscopy #Pancreatobiliary #ESGEAcademy #OpticalDiagnosis #EUS #Ampullectomy
December 11, 2025 at 10:24 AM
Cardiopulmonary fitness in patients undergoing major hepato-pancreatobiliary surgery who are non-anaemic and iron replete vs. non-anaemic and iron deficient: an observational study

#AnSky
doi.org
February 9, 2026 at 9:06 AM
Pancreatobiliary diseases demand clarity that you can quantify.

When managing biliary strictures and dilatations, clinicians need more than visual assessment alone.

https://perspectum.com/products/mrcp/

#Perspectum
March 27, 2026 at 12:00 PM
The articles selected for Pancreatobiliary Pathology Society Journal Watch
pbpath.org/journal-watc...
#pbpath #pancreas #pathology #pancreatobiliary #society #journalwatch #articles #litmaps #bibliometrics
November 9, 2024 at 11:19 AM